Abstract
Simple SummaryEndothelial cells, the innermost layer of blood vessels, play an essential role in the progression of cancer, particularly liver cancer. To develop cancer therapies targeting those cells, the investigation of gene co-expression networks is of great importance. In this study, we investigated the gene expression profile of tumour endothelial cells. We compared it to endothelial cells from non-tumour liver-tissue. Using gene-network based methods, we could identify genes that may play a unique role in liver cancer progression or be a target for cancer therapy. Additionally, we provided a framework for similar analyses in other cancers.Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related death, with tumour associated liver endothelial cells being thought to be major drivers in HCC progression. This study aims to compare the gene expression profiles of tumour endothelial cells from the liver with endothelial cells from non-tumour liver tissue, to identify perturbed biologic functions, co-expression modules, and potentially drugable hub genes that could give rise to novel therapeutic targets and strategies. Gene Set Variation Analysis (GSVA) showed that cell growth-related pathways were upregulated, whereas apoptosis induction, immune and inflammatory-related pathways were downregulated in tumour endothelial cells. Weighted Gene Co-expression Network Analysis (WGCNA) identified several modules strongly associated to tumour endothelial cells or angiogenic activated endothelial cells with high endoglin (ENG) expression. In tumour cells, upregulated modules were associated with cell growth, cell proliferation, and DNA-replication, whereas downregulated modules were involved in immune functions, particularly complement activation. In ENG+ cells, upregulated modules were associated with cell adhesion and endothelial functions. One downregulated module was associated with immune system-related functions. Querying the STRING database revealed known functional-interaction networks underlying the modules. Several possible hub genes were identified, of which some (for example FEN1, BIRC5, NEK2, CDKN3, and TTK) are potentially druggable as determined by querying the Drug Gene Interaction database. In summary, our study provides a detailed picture of the transcriptomic differences between tumour and non-tumour endothelium in the liver on a co-expression network level, indicates several potential therapeutic targets and presents an analysis workflow that can be easily adapted to other projects.
Highlights
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related death, affecting roughly 500,000 people worldwide each year [1]
This study presents a detailed characterisation of HCC-associated tumour endothelial cells on the transcriptome level and an analysis workflow adaptable to other projects
This study systematically investigated the differences between normal and tumour endothelial cells in hepatocellular carcinoma on gene expression level
Summary
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related death, affecting roughly 500,000 people worldwide each year [1]. It arises in a multistep process from preexisting cellular lesions [2], often aggravated due to malnutrition, increased alcohol consumption and obesity [3]. PECAM1, CD34 and classic adhesion molecules like ICAMs are weakly expressed [11]. Non-canonical adhesion molecules (VAP1, DESIGN, LYVE1, and MADCAM) are present, underlining the role of LSEC in the immune cell recruitment [11]. In unstimulated LSEC, chemokines and cytokines are only comparatively weakly expressed [11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
